Tyra Biosciences, Inc. Operating Expenses
Tyra Biosciences, Inc. (TYRA) reported Operating Expenses of $49.00 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-04
- Tyra Biosciences, Inc. operating expenses for the quarter ending 2026-06-30 was $49.00M, a 55.80% increase year-over-year.
- Tyra Biosciences, Inc. operating expenses for the quarter ending 2026-03-31 was $42.00M, a 31.86% increase year-over-year.
- Tyra Biosciences, Inc. operating expenses for the quarter ending 2025-12-31 was $36.52M, a 22.77% increase year-over-year.
- Tyra Biosciences, Inc. operating expenses for the quarter ending 2025-09-30 was $32.94M, a 15.17% increase year-over-year.
- Tyra Biosciences, Inc. operating expenses for fiscal 2025 was $132.76M, a 27.44% increase from fiscal 2024.
- Tyra Biosciences, Inc. operating expenses for fiscal 2024 was $104.18M, a 30.31% increase from fiscal 2023.
- Tyra Biosciences, Inc. operating expenses for fiscal 2023 was $79.94M, a 35.67% increase from fiscal 2022.
- Tyra Biosciences, Inc. operating expenses for fiscal 2022 was $58.93M, a 124.16% increase from fiscal 2021.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $49.00M 10-Q · filed 2026-08-04 | $91.00M 10-Q · filed 2026-08-04 | $127.52M derived: sum of 3 quarters · filed 2026-08-04 | $160.46M derived: sum of 4 quarters · filed 2026-08-04 |
| 2026-03-31 | $42.00M 10-Q · filed 2026-05-13 | $78.51M derived: sum of 2 quarters · filed 2026-05-13 | $111.46M derived: sum of 3 quarters · filed 2026-05-13 | $142.91M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-12-31 | $36.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $69.46M derived: sum of 2 quarters · filed 2026-03-02 | $100.91M derived: sum of 3 quarters · filed 2026-08-04 | $132.76M 10-K · filed 2026-03-02 |
| 2025-09-30 | $32.94M 10-Q · filed 2025-11-05 | $64.40M derived: sum of 2 quarters · filed 2026-08-04 | $96.25M 10-Q · filed 2025-11-05 | $125.99M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-06-30 | $31.45M 10-Q · filed 2026-08-04 | $63.30M 10-Q · filed 2026-08-04 | $93.05M derived: sum of 3 quarters · filed 2026-08-04 | $121.65M derived: sum of 4 quarters · filed 2026-08-04 |
| 2025-03-31 | $31.85M 10-Q · filed 2026-05-13 | $61.59M derived: sum of 2 quarters · filed 2026-05-13 | $90.20M derived: sum of 3 quarters · filed 2026-05-13 | $113.73M derived: sum of 4 quarters · filed 2026-05-13 |
| 2024-12-31 | $29.74M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-02 | $58.35M derived: sum of 2 quarters · filed 2026-03-02 | $81.88M derived: sum of 3 quarters · filed 2026-03-02 | $104.18M 10-K · filed 2026-03-02 |
| 2024-09-30 | $28.60M 10-Q · filed 2025-11-05 | $52.14M derived: sum of 2 quarters · filed 2025-11-05 | $74.43M 10-Q · filed 2025-11-05 | $100.09M derived: sum of 4 quarters · filed 2025-11-05 |
| 2024-06-30 | $23.53M 10-Q · filed 2025-08-14 | $45.85M 10-Q · filed 2025-08-14 | $71.49M derived: sum of 3 quarters · filed 2025-08-14 | $95.45M derived: sum of 4 quarters · filed 2025-08-14 |
| 2024-03-31 | $22.32M 10-Q · filed 2025-05-08 | $47.96M derived: sum of 2 quarters · filed 2025-05-08 | $71.92M derived: sum of 3 quarters · filed 2025-05-08 | $87.93M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $25.63M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | $49.60M derived: sum of 2 quarters · filed 2025-03-27 | $65.61M derived: sum of 3 quarters · filed 2025-03-27 | $79.94M 10-K · filed 2025-03-27 |
| 2023-09-30 | $23.96M 10-Q · filed 2024-11-07 | $39.98M derived: sum of 2 quarters · filed 2024-11-07 | $54.31M 10-Q · filed 2024-11-07 | $69.33M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | $16.01M 10-Q · filed 2024-08-07 | $30.35M 10-Q · filed 2024-08-07 | $45.37M derived: sum of 3 quarters · filed 2024-08-07 | $59.01M derived: sum of 4 quarters · filed 2024-08-07 |
| 2023-03-31 | $14.33M 10-Q · filed 2024-05-09 | $29.35M derived: sum of 2 quarters · filed 2024-05-09 | $43.00M derived: sum of 3 quarters · filed 2024-05-09 | $58.42M derived: sum of 4 quarters · filed 2024-05-09 |
| 2022-12-31 | $15.02M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-19 | $28.66M derived: sum of 2 quarters · filed 2024-03-19 | $44.09M derived: sum of 3 quarters · filed 2024-03-19 | $58.93M 10-K · filed 2024-03-19 |
| 2022-09-30 | $13.64M 10-Q · filed 2023-11-07 | $29.07M derived: sum of 2 quarters · filed 2023-11-07 | $43.91M 10-Q · filed 2023-11-07 | $53.84M derived: sum of 4 quarters · filed 2023-11-07 |
| 2022-06-30 | $15.43M 10-Q · filed 2023-08-10 | $30.26M 10-Q · filed 2023-08-10 | $40.19M derived: sum of 3 quarters · filed 2023-08-10 | $46.83M derived: sum of 4 quarters · filed 2023-08-10 |
| 2022-03-31 | $14.83M 10-Q · filed 2023-05-04 | $24.77M derived: sum of 2 quarters · filed 2023-05-04 | $31.40M derived: sum of 3 quarters · filed 2023-05-04 | $36.91M derived: sum of 4 quarters · filed 2023-05-04 |
| 2021-12-31 | $9.93M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-22 | $16.57M derived: sum of 2 quarters · filed 2023-03-22 | $22.08M derived: sum of 3 quarters · filed 2023-03-22 | $26.29M 10-K · filed 2023-03-22 |
| 2021-09-30 | $6.64M 10-Q · filed 2022-11-03 | $12.15M derived: sum of 2 quarters · filed 2022-11-03 | $16.36M 10-Q · filed 2022-11-03 | $20.03M derived: sum of 4 quarters · filed 2022-11-03 |
| 2021-06-30 | $5.51M 10-Q · filed 2022-08-04 | $9.72M 10-Q · filed 2022-08-04 | $13.40M derived: sum of 3 quarters · filed 2022-08-04 | $15.73M derived: sum of 4 quarters · filed 2022-08-04 |
| 2021-03-31 | $4.21M 10-Q · filed 2022-05-05 | $7.89M derived: sum of 2 quarters · filed 2022-05-05 | $10.22M derived: sum of 3 quarters · filed 2022-05-05 | |
| 2020-12-31 | $3.68M derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-03 | $6.01M derived: sum of 2 quarters · filed 2022-03-03 | $9.30M 10-K · filed 2022-03-03 | |
| 2020-09-30 | $2.33M 10-Q · filed 2021-11-03 | $5.62M 10-Q · filed 2021-11-03 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |